MOLN

Molecular Partners AG ADR
CAPPED RATING

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Molecular Partners AG ADR (MOLN) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (C+); its weakest is Growth (D).

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
C+
Factor Score 2.7 / 5.0
Growth
D
Factor Score 1.3 / 5.0
Profitability
C+
Factor Score 2.8 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C-
Factor Score 1.9 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA 1.2
Rev Growth YoY -100.0%
Gross Margin N/A
Price Return 3M -5.6%
Price Return 12M 17.8%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 156.6
ROE -59.0%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-05 C+ (2.7) D (1.3) C+ (2.8) C (2.4) C- (1.9) C (2.2)
2026-08-04 C+ (2.7) D (1.3) C+ (2.8) C (2.4) C- (1.9) C (2.2)
2026-08-03 C+ (2.7) C- (2.0) C- (2.1) C (2.4) C- (2.0) C (2.2)
2026-08-02 C+ (2.7) C- (2.0) C- (2.0) C (2.4) C- (1.9) C (2.2)